Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...
The FDA has approved a biosimilar of pertuzumab which is indicated for multiple breast cancer settings. The FDA has approved ...
Detailed price information for Daiichi Sankyo Ltd (DSKYF) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback